"I think most of the outside world thought we were crazy when we said we are going to do drug discovery" — Glenn Saldanha

Glenn Saldanha, a serious, highly focused and confident young man, seems extremely certain about his company’s growth path.

Five years ago, Glenmark was a small formulations company, the bulk of its revenues coming from India. Today, it is a radically transformed company focused on daring new drug discovery with two molecules in clinical trials and two landmark deals with leading...

Premium Content
This is a premium article. Your annual or monthly subscription will not give you access if it is outside your subscription period. You can buy it individually
Pay Per Article Gift An Article
Subscriptions
Access will cover your subscription period. Archives not included. Articles outside the subscription period can be bought individually.
Yearly Digital Access Monthly Digital Access
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback